<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39401510</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-2619</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>The Lancet. Respiratory medicine</Title><ISOAbbreviation>Lancet Respir Med</ISOAbbreviation></Journal><ArticleTitle>Empirical antibiotic therapy for sepsis: save the anaerobic microbiota.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S2213-2600(24)00257-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2213-2600(24)00257-1</ELocationID><Abstract><AbstractText>Antibiotics are fundamental in sepsis management; however, the optimal empirical treatment remains debated. Despite anaerobes rarely being the causative pathogen of sepsis, antibiotics targeting them are frequently used, which might lead to unintended consequences. Multiple studies have shown that depletion of commensal anaerobic gut microbes by anti-anaerobic antibiotics influences systemic immunity and is associated with increased mortality in patients with sepsis. However, this knowledge has not yet been translated into clinical practice. When considering empirical coverage of anaerobic pathogens in sepsis, most physicians advocate for a better-safe-than-sorry approach. In this Viewpoint, we argue that anti-anaerobic antibiotics could often result in being sorry rather than safe. We provide an overview of the limited necessity of anaerobic coverage and the potential detrimental effects of anaerobic depletion in sepsis. We aim to raise anaerobic awareness to reduce the unnecessary use of anti-anaerobic antibiotics in empirical sepsis treatment and improve patient outcomes.</AbstractText><CopyrightInformation>Copyright Â© 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kullberg</LastName><ForeName>Robert F J</ForeName><Initials>RFJ</Initials><AffiliationInfo><Affiliation>Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands. Electronic address: r.f.j.kullberg@amsterdamumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haak</LastName><ForeName>Bastiaan W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chanderraj</LastName><ForeName>Rishi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; Medicine Service, Infectious Diseases Section, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI, USA; Weil Institute for Critical Care Research and Innovation, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prescott</LastName><ForeName>Hallie C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Robert P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, USA; Weil Institute for Critical Care Research and Innovation, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiersinga</LastName><ForeName>W Joost</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Division of Infectious Diseases, Department of Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Respir Med</MedlineTA><NlmUniqueID>101605555</NlmUniqueID><ISSNLinking>2213-2600</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of interests HCP reported receiving grants and contracts from the National Institutes of Health/National Heart, Lung and Blood Institute, Agency for Healthcare Research and Quality, Veterans Affairs, Blue Cross Blue Shield of Michigan, and Centers for Disease Control and Prevention. HCP is a co-chair of the Surviving Sepsis Campaign Guidelines. WJW reported receiving grants from the Amsterdam University Medical Centres and European Union (H2020, Eurostars) and performing ad hoc consultancy for AstraZeneca and Shinogi related to COVID-19 (fees paid to host institution). WJW is a panel member of the Surviving Sepsis Campaign Adult Guidelines and chair of the Dutch Working Party on Antibiotic Policy's Sepsis Guidelines. All other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39401510</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(24)00257-1</ArticleId><ArticleId IdType="pii">S2213-2600(24)00257-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle>